Novo Nordisk recently announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month.
The $499-per-month offer for Wegovy was only available via the recently launched NovoCare Pharmacy.
“At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them accessible to and affordable for the communities we serve,” said Dave Moore, Executive Vice President, U.S. Operations and Global Business Development and President of Novo Nordisk Inc. “With the evolution of our Wegovy® savings program, we continue to deliver options that empower people living with obesity to more easily pursue their weight management and health goals.”
Beyond NovoCare® Pharmacy, the Wegovy® savings program offers another avenue for people living with obesity to ensure they are receiving authentic, FDA-approved Wegovy from reputable pharmacies, helping to avoid the significant risks that can be posed by the compounding marketplace, as warned by respected organizations, experts in the medical community, and the FDA. With an FDA-approved medicine like Wegovy, healthcare professionals and patients can have clarity and confidence in knowing the medicine they are using has undergone rigorous review for safety, effectiveness, and quality.
The Wegovy savings offer gives cash-paying patients or those with commercial insurance that does not cover obesity medicines access to a 28-day supply (one box) of Wegovy for $499. This updated offer replaces the previous Wegovy savings offer, which provided cash-paying patients access to Wegovy at a cost of $650 per month. Patients enrolled in government-funded healthcare programs are not eligible for these savings offers. Patients with commercial insurance that does cover Wegovy may pay as little as $0 per month with a maximum savings of $225 for a 28-day supply of Wegovy.
Wegovy (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:
- to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
- that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.
Wegovy contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy is safe and effective for use in children under 12 years of age.
